Abstract
Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor β, RARβ, gene expression. Search of the causes affecting RARβ gene activity has been oriented at identifying possible differences either at the level of one of the RARβ promoters, RARβ2, or at regulatory factors. We hypothesized that loss of RARβ2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RARβ2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RARβ2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RARβ2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2′-deoxycytidine (5-Aza-CdR), led to demethylation within RARβ2 and expression of RARβ indicating that DNA methylation is at least one factor, contributing to RARβ inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RARβ2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RARβ2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RARβ transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RARβ activity, and help to overcome the hurdle of RA-resistance in breast cancer.
Similar content being viewed by others
References
Baust C, Redpath L and Schwarz E . 1996 Int J Cancer 67: 409–416
Bhattacharyya N, Dey A, Minucci S, Zimmer A, John S, Hager G and Ozato K . 1997 Mol Cell Biol 17: 6481–6490
Bird A . 1986 Nature 321: 209–213
Bovenzi V, Le NLO, Cote' S, Sinnet D, Momparler LF and Momparler RI . 1999 Anticancer Drugs 10: 471–476
Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB . 1999 Nature Genet 21: 103–107
Chambon P . 1996 FASEB J 10: 940–954
Chiba H, Clifford J, Metzger D and Chambon P . 1997 Mol Cell Biol 17: 3013–3020
Cote' S and Momparler RL . 1997 Anticancer Drugs 8: 56–61
De The' H, del Mar Vivanco-Ruiz M, Tiollais P, Stunnenberg HG and Dejan A . 1990 Nature 343: 177–180
Eden S, Hashimshony T, Keshet I, Cedar H and Torne AW . 1998 Nature 394: 842
Ferguson AT, Lapidus RG and Davidson NE . 1998 Oncogene 17: 577–583
Folkers GE, van der Burg B and van der Saag PT . 1998 J Biol Chem 273: 32200–32212
Formantici C, Orlandi R, Ronchini C, Pilotti S, Ranzani GN, Colnaghi MI and Menard S . 1999 J Pathol 187: 424–427
Grignani F, Dematteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, et al. 1998 Nature 391: 815–818
Gudas LJ, Sporn MB and Roberts AB . 1994 In The Retinoids Biology, Chemistry and Medicine Raven Press New York pp 443–520
Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S and Zelent A . 1998 Blood 91: 2634–2637
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A and Pandolfi PP . 1998 Nature Genet 18: 126–135
Hebbes TR, Clayton AL, Thorne AW and Crane-Robinson C . 1994 EMBO J 13: 1823–1830
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . 1996 Proc Natl Acad Sci USA 93: 9821–9826
Jones PL and Wolffe AP . 1999 Semin Cancer Biol 9: 339–347
Keshet I, Lieman-Hurwitz J and Cedar H . 1986 Cell 44: 535–543
Li X-S, Shao Z-M, Sheikh MS, Eiseman JL, Sentz D, Jetten AM, Chen J-C, Dawson ML, Aisner S, Rishi AK, Gutierrez P, Schnapper L and Fontana JA . 1995 J Cell Physiol 165: 449–458
Lin RJ, Nagy I, Inoue S, Shao W, Miller Jr WH and Evans RM . 1998 Nature 391: 811–814
Liu Y, Lee M-O, Wang H-G, Li Y, Hashimoto Y, Klaus M, Reed JC and Zhang X-K . 1997 Mol Cell Biol 16: 1138–1149
Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, Howard BH and Ozato K . 1997 Proc Natl Acad Sci USA 94: 11295–11300
Minna JD and Mangeldorf DJ . 1997 J Natl Cancer Inst 89: 602–604
Minucci S and Pelicci P . 1999 Semin Cell Dev Biol 2: 215–225
Ng H-H and Bird A . 1999 Curr Opin Genet Dev 9: 158–163
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN and Bird A . 1998 Nature 393: 386–389
Razin A . 1998 EMBO J 17: 4905–4908
Roman SD, Clarke CL, Hall RE, Alexander IE and Sutherland RL . 1992 Cancer Res 52: 2236–2242
Seewaldt VI, Johnson BS, Parker MB, Collins SJ and Swisshelm K . 1995 Cell Growth Differ 6: 1077–1088
Shao Z-M, Sheikh MS, Chen JC, Kute T, Aisner S, Schnaper L and Fontana JA . 1994 Int J Oncol 4: 849–853
Shang Y, Baumrucker CR and Green MH . 1999 J Biol Chem 274: 18005–18010
Shen S, Kruyt FA, den Hertog J, van der Saag FT and Kruijer W . 1991 DNA Seq 2: 111–119
Smith MA, Parkinson Dr, Cheson BD and Friedman MA . 1992 J Clin Oncol 10: 839–864
Swisshelm K, Ryan K, Lee X, Tsou HC, Peacoque M and Sager R . 1994 Cell Growth Differ 5: 133–141
Toulouse A, Morin J, Pelletier M and Bradley WEC . 1997 BBA 1309: 1–4
Tsou HC, Yao YJ, Xie XX, Ping XL and Peacocke M . 1998 Exp Cell Res 245: 221–227
Valcarel R, Holz H, Garcia Jimenez C, Barettino D and Stunnenberg HG . 1994 Genes Dev 8: 3068–3079
Van der Leede BJ, Folkers GE, Kruyt FA and van der Saag PT . 1992 Biochem Biophys Res Commun 188: 695–702
Wade PA, Jones PL, Vermaak D, Veenstra GJ, Imhof A, Sera T, Tse C, Ge H, Shi YB, Hansen JC and Wolfee AP . 1998 Cold Spring Harb Symp Quant Biol 63: 435–445
Warrell Jr, RP, He LZ, Richon V, Callega E and Pandolfi PP . 1998 J Natl Cancer Inst 90: 1621–1625
Widschwendtner M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendtner A, Mayr A, Marth C and Zeimet AG . 1997 Cancer Res 17: 4158–4161
Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukumanji F, Hortobagy G, Lippman SM, Dhingra K and Lotan R . 1997 Cancer Res 57: 4992–4996
Yoshida M, Horinouchi S and Beppu T . 1995 Bioessays 17: 423–430
Acknowledgements
We thank Drs WEC Bradley (Montreal) and X-Q Zhang (La Jolla) for initial helpful discussions on the idea behind this work and reagents and Dr A Hoogeveen for critical suggestions; Dr M Stampfer for the gift of the HMEC strains; Dr A de Klein for providing DNA from breast tumors. Funding for this work were provided by Associazione Italiana Ricerca sul Cancro (AIRC) and by BC980803 (USA) to N Sacchi.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirchia, S., Ferguson, A., Sironi, E. et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene 19, 1556–1563 (2000). https://doi.org/10.1038/sj.onc.1203456
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203456
- Springer Nature Limited
Keywords
This article is cited by
-
Multiple roles of HOX proteins in Metastasis: Let me count the ways
Cancer and Metastasis Reviews (2020)
-
Polycyclic aromatic hydrocarbon (PAH)–DNA adducts and breast cancer: modification by gene promoter methylation in a population-based study
Cancer Causes & Control (2015)
-
Assessment of DNA methylation status in early stages of breast cancer development
British Journal of Cancer (2013)
-
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
British Journal of Cancer (2012)
-
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients
Breast Cancer Research and Treatment (2012)